




Managing Early Pregnancy: What to know before you refer



Dr. Alice Tan and Dr. Akshay Verma
Mount Sinai Family Health Team
May 17, 2022

Conflicts of Interest

No conflicts of interest or disclosures to note

Acknowledgements

Sincere thanks to the following FM-OB physicians and our Registered Dietician for their support and guidance on this presentation:

Dr. Sabrina Kolker

Dr. Anne Biringer

Dr. Luke Bearss

Dr. Natalie Morson

Dr. Sakina Walji

Dr. Kristina Powles

Dr. Milena Forte

Lauren Rose

Agenda

1. Ontario Perinatal Record 2017
2. Folic Acid Supplementation
3. Placental Markers
4. TSH in First Trimester
5. Nausea/Vomiting in Pregnancy
6. Nutrition in Pregnancy
7. ASA for High Risk Patients
8. Adacel/Flu Immunizations
9. COVID-19 in Pregnancy
10. Exercise in Pregnancy
11. Iron Deficiency Anemia

Q&A Session

Ontario Perinatal Record - Page 1

- 1) Type of conception
- 2) Dating method



Ontario

Ministry of Health and Long-Term Care
Ontario Perinatal Record 1

Last Name		First Name							
Address - street number, street name		Apt/Suite/Unit	Buzzer No						
City/Town	Province	Postal Code	Partner's First Name	Partner's Last Name					
Contact - Preferred		Leave Message <input type="checkbox"/> Y <input type="checkbox"/> N	Contact - Alternate/E-mail		Partner's Occupation	Partner's Education Level	Age		
Date of Birth YYYY/MM/DD	Age at EDB	Language	Interpreter Required <input type="checkbox"/> Y <input type="checkbox"/> N	Occupation	Education Level	Relationship Status	Sexual Orientation		
OHIP Number	Patient File Number		Disability Requiring Accommodation <input type="checkbox"/> Y <input type="checkbox"/> N	Planned Place of Birth		Planned Birth Attendant			
Newborn Care Provider In Hospital				Family Physician/Primary Care Provider In Community					
Allergies or Sensitivities (include reaction)				Medications (include Rx/OTC, complementary/alternative/vitamins and dosage)					
Pregnancy Summary									
LMP YYYY/MM/DD		Cycle q _____	Certain <input type="checkbox"/> Y <input type="checkbox"/> N	Regular <input type="checkbox"/> Y <input type="checkbox"/> N	EDB By LMP YYYY/MM/DD	Dating Method <input type="checkbox"/> T;US <input type="checkbox"/> T;US <input type="checkbox"/> LMP <input type="checkbox"/> IUI YYYY/MM/DD <input type="checkbox"/> Embryo Transfer YYYY/MM/DD <input type="checkbox"/> Other			
Planned Preg <input type="checkbox"/> Y <input type="checkbox"/> N		Contraceptive Type		Last Used YYYY/MM		Final EDB YYYY/MM/DD			
Conception: Assisted <input type="checkbox"/> Y <input type="checkbox"/> N		Details							
Gravida	Term	Preterm	Abortus	Living Children	Stillbirth(s)	Neonatal / Child Death			
Obstetrical History									
Year/ Month	Place of Birth	Gest. (wks)	Labour Length	Type of Birth	Comments regarding abortus, pregnancy, birth, and newborn (e.g. GDM, HTN, IUGR, shoulder dystocia, PPH, OASIS, neonatal jaundice)	Sex M/F	Birth Weight	Breastfed / Duration	Child's Current Health

Ontario Perinatal Record - Page 1

- 1) Genetic history of gametes
- 2) Mental health and substance use screening
- 3) Environmental and social factors impacting pregnancy

Medical History (provide details in comments)			
Current Pregnancy		Family History	
1 Bleeding	<input type="checkbox"/> Y <input type="checkbox"/> N	25 Medical Conditions (e.g. diabetes, thyroid, hypertension, thromboembolic, anaesthetic, mental health)	<input type="checkbox"/> Y <input type="checkbox"/> N
2 Nausea/vomiting	<input type="checkbox"/> Y <input type="checkbox"/> N	Genetic History of Gametes 26 Ethnic/racial background: Egg _____ Age _____ Yrs Sperm _____ 27 Carrier screening: at risk? <input type="checkbox"/> Y <input type="checkbox"/> N • Hemoglobinopathy screening (Asian, African, Middle Eastern, Mediterranean, Hispanic, Caribbean) <input type="checkbox"/> Y <input type="checkbox"/> N • Tay-Sachs disease screening (Ashkenazi Jewish, French Canadian, Acadian, Cajun) <input type="checkbox"/> Y <input type="checkbox"/> N • Ashkenazi Jewish screening panel <input type="checkbox"/> Y <input type="checkbox"/> N 28 Genetic Family History • Genetic conditions (e.g. CF, muscular dystrophy, chromosomal disorder) <input type="checkbox"/> Y <input type="checkbox"/> N • Other (e.g. intellectual, birth defect, congenital heart, developmental delay, recurrent pregnancy loss, stillbirth) <input type="checkbox"/> Y <input type="checkbox"/> N • Consanguinity <input type="checkbox"/> Y <input type="checkbox"/> N Infectious Disease 29 Varicella disease <input type="checkbox"/> Y <input type="checkbox"/> N 30 Varicella vaccine <input type="checkbox"/> Y <input type="checkbox"/> N 31 HIV <input type="checkbox"/> Y <input type="checkbox"/> N 32 HSV Self <input type="checkbox"/> Y <input type="checkbox"/> N Partner <input type="checkbox"/> Y <input type="checkbox"/> N 33 STIs <input type="checkbox"/> Y <input type="checkbox"/> N 34 At risk population (Hep C, TB, Parvo, Toxo) <input type="checkbox"/> Y <input type="checkbox"/> N 35 Other <input type="checkbox"/> Y <input type="checkbox"/> N	
3 Rash/fever/illness	<input type="checkbox"/> Y <input type="checkbox"/> N		
Nutrition			
4 Calcium adequate	<input type="checkbox"/> Y <input type="checkbox"/> N		
5 Vitamin D adequate	<input type="checkbox"/> Y <input type="checkbox"/> N		
6 Folic acid preconception	<input type="checkbox"/> Y <input type="checkbox"/> N		
7 Prenatal vitamin	<input type="checkbox"/> Y <input type="checkbox"/> N		
8 Food access/quality adequate	<input type="checkbox"/> Y <input type="checkbox"/> N		
9 Dietary restrictions	<input type="checkbox"/> Y <input type="checkbox"/> N		
Surgical History		Mental Health / Substance Use	
10 Surgery	<input type="checkbox"/> Y <input type="checkbox"/> N	36 Anxiety Past <input type="checkbox"/> Y <input type="checkbox"/> N Present <input type="checkbox"/> Y <input type="checkbox"/> N	GAD-2 Score _____
11 Anaesthetic complications	<input type="checkbox"/> Y <input type="checkbox"/> N	37 Depression Past <input type="checkbox"/> Y <input type="checkbox"/> N Present <input type="checkbox"/> Y <input type="checkbox"/> N	PHQ-2 Score _____
Medical History		38 Eating disorder	<input type="checkbox"/> Y <input type="checkbox"/> N
12 Hypertension	<input type="checkbox"/> Y <input type="checkbox"/> N	39 Bipolar	<input type="checkbox"/> Y <input type="checkbox"/> N
13 Cardiac / Pulmonary	<input type="checkbox"/> Y <input type="checkbox"/> N	40 Schizophrenia	<input type="checkbox"/> Y <input type="checkbox"/> N
14 Endocrine	<input type="checkbox"/> Y <input type="checkbox"/> N	41 Other	<input type="checkbox"/> Y <input type="checkbox"/> N
15 GI / Liver	<input type="checkbox"/> Y <input type="checkbox"/> N	(e.g. PTSD, ADD, personality disorders)	
16 Breast (incl. surgery)	<input type="checkbox"/> Y <input type="checkbox"/> N	42 Smoked cig within past 6 months	<input type="checkbox"/> Y <input type="checkbox"/> N
17 Gynecological (incl. surgery)	<input type="checkbox"/> Y <input type="checkbox"/> N	Current smoking	_____ cig/day
18 Urinary tract	<input type="checkbox"/> Y <input type="checkbox"/> N	43 Alcohol: Ever drink alcohol?	<input type="checkbox"/> Y <input type="checkbox"/> N
19 MSK/Rheumatology	<input type="checkbox"/> Y <input type="checkbox"/> N	If Yes: Last drink: (when)	_____
20 Hematological	<input type="checkbox"/> Y <input type="checkbox"/> N	Current drinking	_____ drinks/wk
21 Thromboembolic/coag	<input type="checkbox"/> Y <input type="checkbox"/> N	T-ACE Score	_____
22 Blood transfusion	<input type="checkbox"/> Y <input type="checkbox"/> N	44 Marijuana	<input type="checkbox"/> Y <input type="checkbox"/> N
23 Neurological	<input type="checkbox"/> Y <input type="checkbox"/> N	45 Non-prescribed substances/drugs	<input type="checkbox"/> Y <input type="checkbox"/> N
24 Other	<input type="checkbox"/> Y <input type="checkbox"/> N	Lifestyle/Social	
Comments		46 Occupational risks	<input type="checkbox"/> Y <input type="checkbox"/> N
		47 Financial/housing issues	<input type="checkbox"/> Y <input type="checkbox"/> N
		48 Poor social support	<input type="checkbox"/> Y <input type="checkbox"/> N
		49 Beliefs/practices affecting care	<input type="checkbox"/> Y <input type="checkbox"/> N
		50 Relationship problems	<input type="checkbox"/> Y <input type="checkbox"/> N
		51 Intimate partner/family violence	<input type="checkbox"/> Y <input type="checkbox"/> N
		52 Parenting concerns	<input type="checkbox"/> Y <input type="checkbox"/> N
		(e.g. developmental disability, family trauma)	
		53 Other	<input type="checkbox"/> Y <input type="checkbox"/> N

(<https://www.sickkids.ca/siteassets/care--services/for-health-care-providers/lab-testing-requisitions/carrier-screening-tay-sachs-requisition.pdf?fbclid=IwAR0cLo2iPWZ8jBj1XruxDQDNh6CUQehPEfepqcVah0a-4MLtYezkjLVoEGQ>)

Ontario Perinatal Record - Page 2



Ontario

Ministry of Health and Long-Term Care


Ontario Perinatal Record 2

- 1) Pre-pregnancy weight, BMI
- 2) Most recent Pap smear

Last Name					First Name					
Planned Birth Attendant										
Newborn Care Provider										
In Hospital					In Community					
G	T	P	A	L	S	Final EDB YYYY/MM/DD		Family Physician/Primary Care Provider		
Physical Exam					Initial Laboratory Investigations			Second and Third Trimester Lab Investigations		
Ht ____ cm		Pre-pregnancy Wt ____ kg			Test		Result		Test	Result
BP ____		Pre-pregnancy BMI ____			Hb				Hb	
Exam As Indicated					ABO/Rh(D)				Platelets	
Head and neck		N/Abn		MSK	N/Abn		MCV		ABO/Rh(D)	
Breast/nipples		N/Abn		Pelvic	N/Abn		Antibody screen		Repeat Antibodies	
Heart/lungs		N/Abn		Other	N/Abn		Platelets		1hr GCT	
Abdomen		N/Abn				Rubella immune		2 hr GTT		
Exam Comments					HBsAg					
					Syphilis					
					HIV					
					GC					
					Chlamydia					
Last Pap YYYY/MM/DD					Result		Urine C&S			


Ontario Perinatal Record - Page 2

- 1) Ultrasound documentation of placental location

Prenatal Genetic Investigations				
Screening Offered <input type="checkbox"/> Yes <input type="checkbox"/> No		Result	Result	
<input type="checkbox"/> FTS (between 11-13+6wks)			CVS/Amnio	Offered <input type="checkbox"/> Y <input type="checkbox"/> N
<input type="checkbox"/> IPS Part 1(between 11-13+6wks) <input type="checkbox"/> Part 2(between 15-20+6wks)			Other genetic testing	Offered <input type="checkbox"/> Y <input type="checkbox"/> N
<input type="checkbox"/> MSS (between 15-20+6wks) <input type="checkbox"/> AFP (between 15-20+6wks)			NT Risk Assessment 11-13+6wk (multiples)	
Cell-free fetal DNA (NIPT) Offered <input type="checkbox"/> Y <input type="checkbox"/> N			Abnormal Placental Biomarkers	
No Screening Tests				
<input type="checkbox"/> Counseled and declined		Date YYYY/MM/DD	<input type="checkbox"/> Presentation > 20+6wk NIPT offered <input type="checkbox"/> Y <input type="checkbox"/> N	
			Date YYYY/MM/DD	
Ultrasound				
Date	GA	Result		
YYYY/MM/DD				
YYYY/MM/DD		NT Ultrasound (between 11-13+6 weeks)		
YYYY/MM/DD		Anatomy scan (between 18-22wks)	Placental Location	Soft Markers
YYYY/MM/DD				
YYYY/MM/DD				
YYYY/MM/DD				
YYYY/MM/DD				
YYYY/MM/DD				
YYYY/MM/DD				
YYYY/MM/DD				
YYYY/MM/DD				
YYYY/MM/DD				
YYYY/MM/DD				
YYYY/MM/DD				
YYYY/MM/DD		Genetic screening result reviewed with pt/client <input type="checkbox"/>		
YYYY/MM/DD		Approx 22 wks: Copy of OPR 1 & 2 to hospital <input type="checkbox"/> and/or to pt/client <input type="checkbox"/>		

Ontario Perinatal Record - Page 3

- 1) Indications for ASA, progesterone, or HSV suppression
- 2) Tdap, postpartum rubella



Ministry of Health and Long-Term Care

Ontario Perinatal Record 3

Last Name						First Name									
Planned Birth Attendant															
Newborn Care Provider In Hospital						In Community									
Family Physician/Primary Care Provider						Allergies or Sensitivities (include reaction)									
Medications (include Rx/OTC, complementary/alternative/vitamins, include dosage)															
G	T	P	A	L	S	Final EDB YYYY/MM/DD									
Issues (abnormal results, medical/social problems)						Plan of Management / Medication Change / Consultations									
Special Circumstances															
Low dose ASA indicated <input type="checkbox"/> Progesterone indicated (PTB Prevention) <input type="checkbox"/> HSV suppression indicated <input type="checkbox"/> Social (e.g. child protection, adoption, surrogacy)															
GBS															
Rectovaginal swab <input type="checkbox"/> pos <input type="checkbox"/> neg															
Other indications for prophylaxis <input type="checkbox"/> Y <input type="checkbox"/> N															
Recommended Immunoprophylaxis															
Rh(D) neg <input type="checkbox"/> Rh(D) IG given YYYY/MM/DD Additional dose given YYYY/MM/DD				Influenza Discussed <input type="checkbox"/> <input type="checkbox"/> Received <input type="checkbox"/> Declined				Pertussis Discussed <input type="checkbox"/> Up-to-date <input type="checkbox"/> Y <input type="checkbox"/> N Year _____ Received <input type="checkbox"/> Declined <input type="checkbox"/>				Post-partum vaccines discussed <input type="checkbox"/> Rubella <input type="checkbox"/> Other _____			
								Newborn needs <input type="checkbox"/> Hep B prophylaxis <input type="checkbox"/> HIV prophylaxis							

Ontario Perinatal Record 2017 - Page 4, 5

- Additional discussion topics to review:
 - Food/medication safety, infections, and pets
 - Recommended weight gain throughout pregnancy
 - VBAC counselling
 - Mental health
 - Contraception
- New postnatal care tool (page 5)

Folic Acid in Pregnancy

- Target DFE is **0.4 mg daily**
- Typical diet only includes 0.1-0.2 mg of folic acid
- Supplementation associated with decreased risk of NTD, hydrocephalus, facial clefts, urinary tract disease, and limb defects

General recommendation to start folic acid supplementation **3 months before conception and up to 6 weeks postpartum and/or the end of breastfeeding**

Folic Acid Supplementation Guide

Low Risk	Moderate Risk	High Risk
No personal or family risk factors	<ul style="list-style-type: none"> ● Previous NTD in 1st or 2nd degree relative ● PMHx/FMHx of folic-acid sensitive congenital anomalies ● Diabetes, GI malabsorptive conditions, advanced liver/kidney disease, EtOH overuse ● Teratogenic medications 	<ul style="list-style-type: none"> ● Maternal or paternal NTD ● Previous affected pregnancy
0.4mg (3 mo pre-conception to 6 wks PP or end of breastfeeding)	1 mg (3 mo pre-conception to 12 weeks GA) <u>THEN</u> 0.4 to 1 mg (12 wks GA to 6 wks PP or end of breastfeeding)	4 mg folic acid (3 mo pre-conception to 12 wks GA) <u>THEN</u> 0.4 to 1 mg folic acid (12 wks GA to 6 wks PP, or end of breastfeeding)

Types of Folic Acid Supplements

	Folic Acid Content	Examples*
OTC Multivitamins	0.4-0.6 mg	Jamieson
OTC Prenatal Multivitamins	0.4-2 mg	Materna: 0.6 mg Jamieson Prenatal: 1 mg Centrum Prenatal: 1 mg
Prescription Multivitamins	Up to 5 mg	PregVit: 1.1 mg PregVit Folic 5: 5 mg
Prenatal Folic Acid**	0.8-1 mg	Nature's Bounty: 0.8 mg

** pregnant patients should NOT take more than 1 daily dose of multivitamin to achieve desired folic acid dose - instead supplement multivitamin with folic acid tablets

Prenatal Screening - Counselling

Offer all choices for screening (not diagnostic), regardless of whether you think they can afford it

- Multiple marker screening
 - Enhanced first trimester screen (eFTS)
 - Maternal serum screen (MSS-Quad)
- Cell-free fetal DNA testing
 - Non-invasive prenatal test (NIPT)
 - Non-invasive prenatal screen (NIPS) / “Invitae”

Explain benefits, risks / shortcomings and alternatives

- Dating (>7 wk), NT (11+2 - 13+6wk), anatomy (~19-20wk) U/S are considered prenatal screening tests

Have a screening question

Genetic Screening - eFTS

eFTS: 11+2 to 13+3 wk GA

3-4 serum markers (PAPP-A, HCG, AFP, *PLGF*) + NT measurement + maternal age

Screens for T21, T18

Doesn't screen for NTD or spina bifida

Referral Cut-Off Values	Trisomy 21	Trisomy 18
NT > 3.5mm >1:350 risk = +ve screen	89% detection 7% false +ve rate	78% detection 0.2% false +ve rate

Genetic Screening - MSS-Quad

MSS-Quad: 14 - 20+6 wk

4 serum markers (AFP, HCG, uE3, inhibin-A) + maternal age

Screens for T21, T18

Doesn't screen for NTD or spina bifida

Referral Cut-Off Values	Trisomy 21	Trisomy 18
>1:200 risk = +ve screen (reduced to >1:350 risk during covid)	81% detection 5% false +ve rate	60% detection 5% false +ve rate

Genetic Screening - cfDNA

NIPT / NIPS: anytime after 9 or 10 wk

recommend NT U/S between 11+2 and 13+6 wk GA

Screens for T21, T18, T13, fetal sex, sex-chromosome aneuploidy, 22q11 deletion + microdeletion panel

No NTD or spina bifida

Trisomy 13	Trisomy 21	Trisomy 18
88% detection <0.1% false +ve rate	>99% detection 0.1% false +ve rate	95% detection <0.1% false +ve rate

Genetic Screening - cfDNA

OHIP-Funded NIPT	Private Pay - NIPT / NIPS
<ul style="list-style-type: none">● Positive eFTS or MSS● Maternal age >40 at EDD● NT > 3.5 mm● Hx of T21, T18, T13● Twin pregnancy	<ul style="list-style-type: none">● Harmony (DynaCare) - \$495 (+\$200)● Panorama (LifeLabs) - \$550 (+\$195)● Invitae NIPS - US \$99

N.B: Invitae takes ~2wks, sent to USA

Sex-Chromosome Aneuploidy and Microdeletion Panels

Sex-Chromosome Aneuploidy	Microdeletion Panels
<p>Disorders of chromosome 23</p> <ul style="list-style-type: none">● 45X (Turner's)● 47XXX (Triple X)● 47XXY (Klinefelter)● 47 XYY (Jacob's)	<ul style="list-style-type: none">● Small subset of very rare genetic conditions (e.g: DiGeorge, Prader-Willi, Langer-Giedion)● 1:5,000 to 1:50,000 pregnancies● High false positive rate <p>Current recommendations do NOT support microdeletion screening</p>

Failed or No-Call NIPT

Commonly due to insufficient fetal DNA

Possibly due to chromosomal abnormality (low likelihood)

Options:

- Repeat blood draw (free)
- Alternative screening (i.e: eFTS, MSS depending on GA)
- Referral to genetics counselor
- Invasive diagnostic testing

TSH Screening in Pregnancy


TSH screening in pregnancy recommended in:

- Maternal age >30 years, BMI > 40
- Personal or family history of thyroid dysfunction
- T1DM or other autoimmune disorder
- Previous head/neck radiation or thyroid surgery
- Hx pregnancy loss, preterm deliveries, or infertility
- Taking amiodarone/lithium, or recent iodinated contrast agent

<https://pubmed.ncbi.nlm.nih.gov/10451459/>

<https://www.cadth.ca/sites/default/files/pdf/htis/2016/RB1038%20Thyroid%20Screening%20Final.pdf>

TSH Management Algorithm



Subclinical Hypothyroidism: levothyroxine 25-50 mcg daily

Overt Hypothyroidism: levothyroxine 50-100 mcg daily

*** taken separately from PNV, separately from calcium and iron by 2 hours, and not within 1 hour of meal*

Monitor TSH and fT4:

- q4 weeks until 20 wks GA, then
- 1x between 26-32 wks GA

Target TSH = 0.1-2.5 through all trimesters ***2.5-4 if hx multiple miscarriages*

Pre-existing Hypothyroidism

Pre-Conception	Pregnancy Confirmed	Postpartum
Adjust LT4 with Target TSH < 2.5	Increase LT4 by 30% <i>** may require dose increase of 40-50% if prior thyroidectomy, ablation, or thyroid ca</i>	Immediately return to pre-pregnancy LT4 dosage Repeat TSH at 6 weeks postpartum

Nausea and Vomiting in Pregnancy

Lifestyle Recommendations

Dietary

- Small, regular meals
 - Avoid having an empty stomach (also avoid being too full)
- Bland foods, salty foods and high protein foods
- Separate solids and liquids
- Avoid high fat or strongly odorous foods

Adequate sleep

Ginger 250mg PO QID PRN

Acupressure (P6 Nei Guan Point)

Nausea and Vomiting in Pregnancy

First-Line	Second-Line	Third-Line
<ul style="list-style-type: none">● Vitamin B6 (pyridoxine) 10mg PO QID PRN● Diclectin 10mg (doxylamine 10mg + pyridoxine 10mg) PO TID PRN<ul style="list-style-type: none">○ Max 4 tablets / day (1-1-2 / 2-1-1 etc.)	<ul style="list-style-type: none">● Dimenhydrinate (gravol) 50mg q4-6 PO / PR	<ul style="list-style-type: none">● Metoclopramide 5-10mg q8h PO/IM● Chlorpromazine 10-25mg q4-6h PO, or 25-50mg q4h IM● Prochlorperazine 5-10mg q6-8h PO/PR/IM● Promethazine 12.5 - 25mg q4-6h PO/IM <p>☐ <i>Ondansetron 4mg TID</i></p>

Aspirin Use in Pregnancy

Major Risk Factors	Minor Risk Factors
<ul style="list-style-type: none">● Antiphospholipid antibody syndrome● Chronic HTN (pre-pregnancy)● Pre-existing diabetes mellitus● Pre-eclampsia in a prior pregnancy● Prev. IUGR● Pre-pregnancy BMI >30● Assisted reproductive technology	<ul style="list-style-type: none">● Prior placental abruption● Multifetal pregnancy (twins, triplets)● Chronic kidney disease● Previous stillbirth● Maternal age > 40y● Nulliparity● Systemic Lupus Erythematosus / SLE

Start Aspirin in patients who have 1 major risk factor or ≥ 2 minor risk factors

Aspirin Use in Pregnancy

Benefits	Potential Risks
<ul style="list-style-type: none">● Pre-eclampsia● Preterm Birth● Small for Gestational Age● Intrauterine Growth Restriction● Perinatal Mortality	<ul style="list-style-type: none">● Bleeding (maternal)● Postpartum Hemorrhage● Fetal Intracranial Hemorrhage

Aspirin Use in Pregnancy

Aspirin dosed at 162mg daily

- Start between 12 - 16 weeks gestation
 - Latest can be started by 20 weeks
- Stopped around 36-38 weeks gestation (sometimes term)

Nutrition in Pregnancy - How Much to Eat?

- **1st trimester:** no extra calories
- **2nd-3rd trimester:** extra 350-450 kcal/day (extra 2-3 food guide servings)

Choose **quality (nutrient rich foods)**, not quantity!

Pre-Pregnancy BMI	Recommended Total Weight Gain During Pregnancy		Recommended <u>weekly</u> rate of weight gain (in 2nd/3rd trimester)
	kg	lbs	
BMI < 18.5	12.5 - 18	28 - 40	0.5 kg (1.1 lbs)
BMI 18.5 - 24.9	11.5 - 16	25 - 35	0.4 kg (0.9 lbs)
BMI 25.0 - 29.9	7 - 11.5	15 - 25	0.3 kg (0.6 lbs)
BMI > 30	5 - 9	11 - 20	0.2 kg (0.5 lbs)

<http://www.hc-sc.gc.ca/fn-an/pubs/nutrition/guide-prenatal-eng.php>

<http://www.hc-sc.gc.ca/fn-an/nutrition/prenatal/ewba-mbsa-eng.php>

Coffee and Tea

Pregnancy caffeine recommendation	Type	Caffeine Amount	Herbal Teas
Health Canada ≤ 300 mg/day SOGC ≤ 2 cups/day ACOG ≤ 200 mg/day	1 cup of brewed coffee (8 oz)	135-180 mg	AVOID: Chamomile, aloe, buckthorn bark, coltsfoot, comfrey, duck roots, juniper berries, labrador tea, lobelia, pennyroyal, sassafras, senna leaves Safe in moderation (2-3 cups/day): Citrus peel, orange peel, ginger root, peppermint, rose hip
	1 cup of instant coffee (8 oz)	75-105 mg	
	1 oz espresso	75 mg	
	1 oz black/green tea	30-80 mg	
	Energy drink (8 oz)	80-100 mg	
	1 oz dark chocolate	20-25mg	

https://www.unlockfood.ca/en/Articles/Caffeine/Facts-on-Caffeine.aspx#.VhatOFy4k_U
<https://www.canada.ca/en/public-health/services/pregnancy/caffeine.html>
<https://www.albertahealthservices.ca/assets/info/nutrition/if-nfs-ng-pregnancy.pdf>

Foodborne Illnesses

Pregnant individuals should AVOID:

- Raw or undercooked meat, eggs, seafood
- Unpasteurized products (ALL soft/semi-soft cheeses, raw milk, juices/ciders)
- Ready-to-eat meats (e.g. deli meats, refrigerated pâté, cold hot dogs)

- Raw sprouts (e.g. alfalfa, clover, radish, mung bean)
- Refrigerated smoked seafood
- Prepackaged or prepared fruit/vegetable salads

<https://www.canada.ca/en/public-health/services/diseases/listeriosis/risk-listeriosis.html>

<https://www.unlockfood.ca/en/Articles/Pregnancy/Food-safety-during-pregnancy.aspx#.VvLF4pMrKcx>

<https://www.cfp.ca/content/60/4/334>

<https://www.acog.org/womens-health/faqs/listeria-and-pregnancy#:~:text=Listeriosis%20can%20cause%20mild%2C%20flu,do%20not%20have%20any%20symptoms.>

Methylmercury in Fish

LIMIT to < 150g per month	RECOMMENDED to have 150g weekly
<ul style="list-style-type: none">● Tuna● Shark● Swordfish● Marlin● Orange roughy● Escolar● Canned albacore tuna < 300g/month	<ul style="list-style-type: none">● Salmon● Trout● Haddock● Sole● Pollock● Canned light tuna

Important Nutrients in Pregnancy

Vitamin D3
400 - 1000 IU/day

Recommend supplement

Sinai and Canadian Pediatric Society recommends 2000IU per day during COVID pandemic

Calcium
1000 mg/day

Recommend diet only

No additional benefit to supplement in normal calcium intake populations
*** Consider increased need in teen pregnancy re: bone loss*

Folic Acid
Min 400 mcg/day

Recommend PNV

Difficult to achieve via diet alone (ie: folate --> dark green leafy veggies, lentils, enriched flour products)

Important Nutrients in Pregnancy

Omega 3
300 mg EPA+DHA

Iodine
220 mcg/day

Iron
27 mg/day

Recommend diet first: 150g weekly of **Recommend PNV**

fatty fish (e.g. salmon, anchovies, herring, sardines, rainbow trout)

Current PNVs have sufficient amount

Second-line supplement:

< 3g/day likely safe; NO cod liver oil re: Vit A.

C/I: vaginal bleeding or coagulopathy

or blood thinners; look for Natural

Product Number (NPN) = HC approval, safe in pregnancy

Recommend diet first: Meat products are better absorbed, however fortified grains are source as well

Ferritin <30 ug/L in pregnancy = iron deficiency

Immunizations in Pregnancy - Tdap (Adacel)

Tdap vaccine helps to prevent pertussis in infants under 1 year (highest risk of infection and hospitalisation)

A study done between 2006-2015 found:

- Incidence = 71.2/100,000
- Hospitalization rate = 33.6/100,000
- Infants < 2 mo – 40.5% of special care unit admissions

Immunizations in Pregnancy - Tdap (Adacel)

SOGC recommends Tdap for all pregnant women, between 27 - 32 weeks (ideally), irrespective of immunization history

- Can be given between 21-32
- Given even if they had Tdap within last 2 years
- Immunize partners, family members and caregivers at least 2 weeks before delivery

Immunizations in Pregnancy - Influenza

Pregnancy confers an increased risk of influenza-related morbidity and mortality

- Hospitalisation rates increase with increasing gestational age
- Evidence of adverse neonatal outcomes with maternal influenza in pregnancy

Vaccination provides significant benefits

- Reduces febrile influenza-like illness in pregnant women by ~30%
- Reduces proven influenza infection in infants up to 6 months by 63% (passive Ab transfer)

Immunizations in Pregnancy - Influenza

SOGC highly recommends inactivated or attenuated influenza vaccine (i.e: not the live intranasal vaccine) in pregnant and breastfeeding women

- Recommend all family members and caregivers receive influenza vaccine

COVID-19 Immunization in Pregnancy

COVID-19 vaccination is **recommended** during pregnancy in **any trimester and while breastfeeding**

- Any available COVID-19 vaccine can be used
- No longer need to wait before/after other vaccines

COVID-19 Immunization in Pregnancy

Fertility	Pregnancy	Breastfeeding
<ul style="list-style-type: none">• No negative effect on sperm parameters, oocyte/follicular function, fertilization and embryo implantation	<ul style="list-style-type: none">• Reduced maternal ICU admission, ventilation, and death• COVID-19 antibodies cross placenta as soon as two weeks post dose, with no crossing of mRNA content• No negative effect on pregnancy outcomes	<ul style="list-style-type: none">• COVID-19 antibodies are detected in human breastmilk• COVID-19 mRNA not detected in human milk

COVID-19 Immunization in Pregnancy

US v-safe pregnancy registry published the following data:

- 85% of patients reported injection-site pain as the most frequent S/E
- Fatigue (26%), headache (16%), myalgia (9%), chills (3%) and fever (3%) were less frequent S/E

No statistically significant difference in rates of:

- Spontaneous abortion (treatment 12.6% vs. control 10-26%)
- Preterm delivery (treatment 9.4% vs. control 8-15%)
- SGA fetus (treatment 3.2% vs. control 3.5%)
- Congenital anomalies (treatment 2.2% vs. control 3.5%)
- Stillbirth (treatment 0.1% vs. control <1%)
- Neonatal death (treatment 0% vs. control <1%)

COVID-19 in Pregnancy

Maternal Consequences of COVID-19	Fetal Consequences of COVID-19
<ul style="list-style-type: none">↑ risk of ICU admission, need for mechanical ventilation↑ risk of pre-eclampsia↑ maternal death	<ul style="list-style-type: none">Modest ↑ risk of pre-term delivery9x ↑ prevalence of low birth weight

COVID-19 Management in Pregnancy (Mount Sinai Hospital-specific):

- **If COVID +ve in 1st/2nd trimester:** serial growth US q4 weeks starting at 24 weeks
- **If COVID +ve past 24 wks GA:** growth US at recovery, and then serial growth US q4 weeks
- Inadequate data to recommend for/against IOL if mild COVID diagnosed at term

Exercise in Pregnancy

Joint SOGC and CSEP guidelines (2019) aims to elicit a cognitive shift in practitioners

“Prenatal physical activity should be considered a first-line **therapy for reducing** the risk of **pregnancy complications**, and enhancing maternal physical and mental health”

Exercise in Pregnancy

Target populations:

- Previously inactive patients
 - GDM
 - Overweight or obese (BMI > 25 kg/m²)
-
- *Maternal age > 35*

Benefits include reductions in:

- Excessive weight gain (32% RRR, CI 0.57 - 0.80)
- Gestational HTN (39% RRR, CI 0.43 - 0.85)
- Pre-eclampsia (41% RRR, CI 0.37 - 0.90)
- GDM (38% RRR, CI 0.52 - 0.75)
- LGA babies
- Urinary incontinence (50% RRR, CI 0.37 - 0.68)
- Depression (67% RRR, CI 0.21 - 0.53)
- Lumbo-pelvic pain severity
- Instrumental delivery (24% RRR, CI 0.63 - 0.92)

Dose-dependent response with bigger effect in previously sedentary women

Not associated with:

- Miscarriage
- Stillbirth or neonatal death
- Preterm birth (or PROM / PPROM)
- Induction of labour
- Low birthweight
- Neonatal hypoglycaemia
- Birth defects
- Birth complications

SOGC / CSEP Recommendations

150 minutes of moderate-intensity physical activity each week

- Spread over a minimum of 3 days
- Resistance training is recommended
- Consider yoga and/or gentle stretching
- Pelvic floor muscle training daily

Table 2 Absolute and relative contraindications to physical activity during pregnancy

Absolute contraindications	Relative contraindications
▶ Ruptured membranes, premature labour.	▶ Recurrent pregnancy loss.
▶ Unexplained persistent vaginal bleeding.	▶ History of spontaneous preterm birth.
▶ Placenta praevia after 28 weeks' gestation.	▶ Gestational hypertension.
▶ Pre-eclampsia.	▶ Symptomatic anaemia.
▶ Incompetent cervix.	▶ Malnutrition.
▶ Intrauterine growth restriction.	▶ Eating disorder.
▶ High-order multiple pregnancy (eg, triplets)	▶ Twin pregnancy after the 28th week.
▶ Uncontrolled type I diabetes, uncontrolled hypertension or uncontrolled thyroid disease.	▶ Mild/moderate cardiovascular or respiratory disease.
▶ Other serious cardiovascular, respiratory or systemic disorder.	▶ Other significant medical conditions.

Iron Deficiency in Pregnancy

- Iron deficiency affects >30% pregnancies in Canada
- Recommend initial **CBC and ferritin** during 1st trimester, and repeat at 24-28 wks GA
 - Iron deficiency anemia if Hb:
 - < 110 in 1st trimester
 - < 105 in 2nd/3rd trimester
 - < 100 during postpartum period
 - Iron deficiency without anemia if ferritin < 30 ug/L

Iron Deficiency Anemia

**Ensure taking
iron-containing
PNV daily**

Counsel on iron-rich
foods



**Initiate ferrous iron
supplement
(40-100mg of
elemental iron)**

Counsel to take
vitamin C on empty
stomach if tolerated.
Avoid taking with
calcium, caffeine,
fibre, PPI/antacids,
levothyroxine



**Repeat CBC q2-4 weeks until
hemoglobin stabilizes. Continue
iron until 6 weeks postpartum**

Hb should rise 10g/L in 2 weeks, or
20g/L in 4 weeks

Iron Formulations

Oral

- Ferrous salts
- Polysaccharide iron complex
- Chelated iron

Parenteral

- Iron sucrose
- Ferric derisomaltose


Table 1: Oral and parenteral iron preparations*

Generic name	Brand name	Daily or alternate day dosing	Dose, mg	Elemental iron, mg/tab	Daily estimated cost, \$†
Oral iron					
Ferrous gluconate	Floradix, Floravit	1 to 2 tabs	300	35	0.10
Ferrous sulfate	Ferodan, Ferrotrate	1 tab	300	60	0.20
Ferrous fumarate	Palafer, EuroFer	1 tab	300	100	0.25
Ferrous bisglycinate	Ferrochel, CanPrev	1 tab	25	25	0.30
Polysaccharide iron complex	Feramax	1 tab	150	150	0.75
Heme iron polypeptide	OptiFerA, Proferrin	2 to 3 tabs	398	11	2.40
Parenteral iron					
Iron sucrose	Venofer	200–300 mg in a single dose over 2 h§		—	375
Ferric derisomaltose‡	Monoferic	500–1500 mg in a single dose over 30 to 60 min§		—	450–900

Parenteral Iron (~\$200)

Indications	Contraindications
<p><u>First-line:</u> Gastric bypass/resection, or receiving TPN Hb < 80 at any point of pregnancy Hb < 90 and symptomatic Planned surgery in < 4 weeks, with Hb < 120 > 34 wks GA</p> <p><u>Second-line:</u> Failure of oral iron therapy</p>	<p>1st trimester of pregnancy Previous IV iron hypersensitivity Myelodysplasia Aplastic anemia Leukemia (acute/chronic) Myelofibrosis Polycythemia rubra vera</p>
<p>Risks of IV iron include iatrogenic hemosiderosis (e.g. excessive IV therapy), hypersensitivity reactions, and hypotension</p>	
<p>Generally 300 mg</p>	

Thank you!
Please provide
your feedback:



Survey Link:

https://dfcmutorontoca.qualtrics.com/jfe/form/SV_bHQxnckrLwSirYy



**BOOK RELEASE
SUMMER 2022**

**FOLLOW
US ON TWITTER
@TEACHPERINATAL**

Teaching Perinatal Care A Practical Guide

Teaching Perinatal Care

A Practical Guide

ANNE BIRINGER, MD
SABRINA KOLKER, MD
WARREN RUBENSTEIN, MD